ArticleScience immunology2023
Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques.
Open access · greenAbstract read
In one paragraph
Article in Science immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 28 citations in OpenAlex.
- A Nomogram Integrating CD169%, Neutrophil CD64 Index, and C-Reactive Protein for Differential Diagnosis of Mixed Respiratory Tract Infections.Diagnostics (Basel, Switzerland) · 2026Article
- Dose-dependent activation of the Hippo pathway by Type I and Type III interferons suppresses tissue repair by human bronchial epithelial cells.PLoS biology · 2026Article
- Inflammation from mild COVID-19 results in persistent neurological and behavioral changes in rhesus macaques.Research square · 2025Article
- The Role of Metabolites in CSF on NAFLD Development: A Mendelian Randomisation Analysis.Endocrinology, diabetes & metabolism · 2025Article
- Increase of Inhibitory Siglec receptors on T cells mitigates severe immune reactions during acute viral infections.PNAS nexus · 2025Article
- Antiviral and immunomodulatory effects of Chaihu Guizhi decoction in an acute depression-like mouse model infected with influenza A virus.Animal models and experimental medicine · 2025Article
- Distinctive Temporal Profiles of Interferon-Stimulated Genes in Natural Infection, Viral Challenge, and Vaccination.Viruses · 2025Article
- SIGLEC1 ubiquitination and degradation induced by MARCHF3 protects ARPE19 retinal cells from high glucose-induced oxidative stress, inflammation, and apoptosis.International ophthalmology · 2025Article
- Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques.PLoS pathogens · 2025Article
- Article
- Transient anti-interferon autoantibodies in the airways are associated with recovery from COVID-19.Science translational medicine · 2024Article
- IRF3 inhibits inflammatory signaling pathways in macrophages to prevent viral pathogenesis.Science advances · 2024Article
- The assembly of neutrophil inflammasomes during COVID-19 is mediated by type I interferons.PLoS pathogens · 2024Article
- Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2.International journal of molecular sciences · 2024Review
- Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques.bioRxiv : the preprint server for biology · 2024Article
- Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity.Nature communications · 2024Article
- Harnessing the power of IFN for therapeutic approaches to COVID-19.Journal of virology · 2024Review
- The role of HPV11 E7 in modulating STING-dependent interferon β response in recurrent respiratory papillomatosis.Journal of virology · 2024Article
- Yin and yang of interferons: lessons from the coronavirus disease 2019 (COVID-19) pandemic.Current opinion in immunology · 2024Review
- Review
Corrections and comments
- Update of
Authors and funding
42 authors at 10 institutions in 5 countries.
Elise G VioxDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-2788-4585
Timothy N HoangDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-7781-1130
Amit A UpadhyayDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-0952-4164
Rayhane NchiouaInstitute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany.
Maximilian HirschenbergerInstitute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany.ORCID 0000-0001-8766-1271
Zachary StronginDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Gregory K TharpEmory NPRC Genomics Core Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0003-3075-755X
Maria PinoDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0003-4954-5215
Kevin NguyenDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Justin L HarperDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-6948-3501
Matthew GagneVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-5526-6162
Shir MarcianoDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel.ORCID 0000-0001-8506-9549
Arun K BoddapatiEmory NPRC Genomics Core Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Kathryn L PellegriniEmory NPRC Genomics Core Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-5089-5477
Arpan PradhanDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0003-3924-745X
Jennifer Tisoncik-GoCenter for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, Seattle, WA 98109, USA.
Leanne S WhitmoreCenter for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, Seattle, WA 98109, USA.
Kirti A KarunakaranDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Melissa RoyDivision of Pathology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Shannon KirejczykStageBio, 5930 Main St., Mount Jackson, VA 22842, USA.ORCID 0000-0002-5900-4239
Elizabeth H CurranDivision of Pathology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0009-0007-5364-0035
Chelsea WallaceDivision of Animal Resources, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.
Jennifer S WoodDivision of Animal Resources, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0001-8918-8510
Fawn Connor-StroudDivision of Animal Resources, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0003-3981-8654
Emily A VoigtRNA Vaccines Group, Access to Advanced Health Institute, Seattle, WA 98102, USA.ORCID 0000-0001-5177-4063
Christopher M MonacoDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0001-7802-6188
David E GordonDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0001-7954-0306
Sudhir P KasturiDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-6421-2040
Rebecca D LevitDepartment of Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0001-5405-8716
Michael GaleCenter for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, Seattle, WA 98109, USA.ORCID 0000-0002-6332-7436
Thomas H VanderfordDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-5068-0900
Guido SilvestriDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0001-6602-2470
Kathleen Busman-SahayVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-8549-0023
Jacob D EstesVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR 97006, USA.ORCID 0000-0002-9652-6394
Monica VaccariDivision of Immunology, Tulane National Primate Research Center, Covington, LA 70433, USA.ORCID 0000-0002-4514-2681
Daniel C DouekVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Konstantin M J SparrerInstitute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany.ORCID 0000-0002-8682-1779
R Paul JohnsonDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-2600-120X
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany.ORCID 0000-0002-7052-2360
Gideon SchreiberDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 76100, Israel.ORCID 0000-0002-2922-5882
Steven E BosingerDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-2116-5061
Mirko PaiardiniDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA.ORCID 0000-0002-7276-3600
Emory University · USUniversität Ulm · DEUniversity of Washington · USNational Institutes of Health · USWeizmann Institute of Science · ILChildren's Cancer Therapy Development Institute · USMount St. Joseph University · USOregon National Primate Research Center · USProgram for Appropriate Technology in Health · USTulane University · US
Funding
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MWashington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MTulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MThe Genome Analysis CoreZICAI005133 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2019 to 2025
$16.9MVery early drivers of neutrophilic inflammation in cardiac ischemia-reperfusionR01HL140223 · NHLBI · EMORY UNIVERSITY · PI Rebecca Diane Levit · 2018 to 2026
$4.4MIllumina NovaSeq 6000 High Throughput DNA Sequencer for Emory UniversityS10OD026799 · OD · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2019 to 2019
$985kNHLBI NIH HHS R01 HL140223NIAID NIH HHS P30 AI050409NIH HHS P51 OD010425NIH HHS P51 OD011092NIH HHS P51 OD011104NIH HHS P51 OD011132NIH HHS S10 OD026799
Abstract
Type I interferons (IFN-I) are critical mediators of innate control of viral infections but also drive the recruitment of inflammatory cells to sites of infection, a key feature of severe coronavirus disease 2019. Here, IFN-I signaling was modulated in rhesus macaques (RMs) before and during acute SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection using a mutated IFN-α2 (IFN-modulator; IFNmod), which has previously been shown to reduce the binding and signaling of endogenous IFN-I. IFNmod treatment in uninfected RMs was observed to induce a modest up-regulation of only antiviral IFN-stimulated genes (ISGs); however, in SARS-CoV-2-infected RMs, IFNmod reduced both antiviral and inflammatory ISGs. IFNmod treatment resulted in a potent reduction in SARS-CoV-2 viral loads both in vitro in Calu-3 cells and in vivo in bronchoalveolar lavage (BAL), upper airways, lung, and hilar lymph nodes of RMs. Furthermore, in SARS-CoV-2-infected RMs, IFNmod treatment potently reduced inflammatory cytokines, chemokines, and CD163
Indexed as
COVID-19Interferon Type IAnimalsAntiviral AgentsInflammationMacaca mulattaSARS-CoV-2Virus ReplicationAntiviral AgentsInterferon Type I
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.